Protagonist Therapeutics
PTGX
137 hedge funds and large institutions have $1.22B invested in Protagonist Therapeutics in 2023 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 31 closing their positions.
220% more call options, than puts
Call options by funds: $42.3M | Put options by funds: $13.2M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
133% more capital invested
Capital invested by funds: $525M → $1.22B (+$700M)
6.04% more ownership
Funds ownership: 97.73% → 103.77% (+6%)
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
1% more funds holding
Funds holding: 136 → 137 (+1)
4% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$63.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$28.6M |
| 4 |
RI
RTW Investments
New York
|
+$16.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$25.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$23.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$17.4M |
| 5 |
Morgan Stanley
New York
|
-$14.6M |
PTGX Hedge Fund Activity: Q1 2023 in Review
137 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2023, worth a combined $1.22B — up 133% from $525M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PTGX positions and 31 closed out — a net gain of 2 holders — while 43 added to existing stakes and 45 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $63.4M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $25.8M sold.
- 137 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2023, up from 136 in Q4 2022.
- Funds reported $1.22B of Protagonist Therapeutics stock for Q1 2023, up 133% quarter-over-quarter.
- 33 funds opened new Protagonist Therapeutics positions in Q1 2023 and 31 closed out, a net change of +2 holders.
- The largest Protagonist Therapeutics buyer in Q1 2023 was BVF Inc, an estimated $63.4M added.
- The largest Protagonist Therapeutics seller in Q1 2023 was Bain Capital Life Sciences Investors, an estimated $25.8M sold.
Based on aggregated 13F filings for Q1 2023.